Variability of oral bioavailability for low dose methotrexate in rats
- PMID: 11808864
- DOI: 10.1007/BF03226376
Variability of oral bioavailability for low dose methotrexate in rats
Abstract
The effects of food, antibiotics, diclofenac sodium (DS) and methotrexate (MTX) on oral bioavailability (BA) of MTX were examined in rats. Feeding didn't vary the plasma concentrations after intravenous dosing of 0.5 mg/kg MTX, but enhanced those after oral dosing, and the oral BA. The twice daily oral doses of 40 mg/kg neomycin sulfate (NS) or mixed antibiotics (200 mg/kg NS + 200 mg/kg streptomycin sulfate + 200 mg/kg bacitracin) for 5 days didn't influence the plasma concentrations after intravenous dosing of 0.5 mg/kg MTX, but induced the decreased Cmax and the delayed MRT after oral dosing. The plasma concentrations after intravenous or oral dosing of 2.5 mg/kg MTX in rats orally dosed with 1 or 5 mg/kg/day DS for 4 days were similar to those in the control rats, while the pre-treatment of 25 mg/kg/day DS delayed the elimination of MTX but didn't change the oral BA. The plasma concentrations after intravenous or oral dosing of 2.5 mg/kg MTX in rats, which received the intermittent oral doses of 7.5 mg/kg/3 doses/week MTX for 4 weeks, were comparable to those in the control rats, but the daily pre-treatment of 0.2 mg/kg/day MTX for 4 weeks increased the plasma concentrations after oral dosing, and the BA.
Similar articles
-
Species differences in oral bioavailability of methotrexate between rats and monkeys.Biol Pharm Bull. 2000 Mar;23(3):334-8. doi: 10.1248/bpb.23.334. Biol Pharm Bull. 2000. PMID: 10726889
-
CAN a P-gp modulator assist in the control of methotrexate concentrations in the rat brain? -inhibitory effects of rhodamine 123, a specific substrate for P-gp, on methotrexate excretion from the rat brain and its optimal route of administration.J Vet Med Sci. 2017 Feb 14;79(2):320-327. doi: 10.1292/jvms.16-0315. Epub 2016 Dec 5. J Vet Med Sci. 2017. PMID: 27916761 Free PMC article.
-
St. John's wort significantly increased the systemic exposure and toxicity of methotrexate in rats.Toxicol Appl Pharmacol. 2012 Aug 15;263(1):39-43. doi: 10.1016/j.taap.2012.05.020. Epub 2012 Jun 12. Toxicol Appl Pharmacol. 2012. PMID: 22699020
-
What can clinicians learn from therapeutic studies about the treatment of acute oral methotrexate poisoning?Clin Toxicol (Phila). 2017 Feb;55(2):88-96. doi: 10.1080/15563650.2016.1271126. Clin Toxicol (Phila). 2017. PMID: 28084171 Review.
-
Methotrexate bioavailability.Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S27-32. Epub 2010 Oct 28. Clin Exp Rheumatol. 2010. PMID: 21044430 Review.
Cited by
-
Preparation and In Vitro/In Vivo Characterization of Polymeric Nanoparticles Containing Methotrexate to Improve Lymphatic Delivery.Int J Mol Sci. 2019 Jul 5;20(13):3312. doi: 10.3390/ijms20133312. Int J Mol Sci. 2019. PMID: 31284483 Free PMC article.
-
Localised and sustained intradermal delivery of methotrexate using nanocrystal-loaded microneedle arrays: Potential for enhanced treatment of psoriasis.Eur J Pharm Sci. 2020 Sep 1;152:105469. doi: 10.1016/j.ejps.2020.105469. Epub 2020 Jul 15. Eur J Pharm Sci. 2020. PMID: 32679177 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Miscellaneous